

Resource Summary Report

Generated by [ASWG](#) on Aug 3, 2026

QIAGEN

RRID:SCR_008539

Type: Tool

Proper Citation

QIAGEN (RRID:SCR_008539)

Resource Information

URL: <http://www.qiagen.com>

Proper Citation: QIAGEN (RRID:SCR_008539)

Description: A commercial organization which provides assay technologies to isolate DNA, RNA, and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analysis.

Synonyms: QIAGEN

Resource Type: commercial organization

Resource Name: QIAGEN

Resource ID: SCR_008539

Alternate IDs: nif-0000-31384

Record Creation Time: 20220129T080248+0000

Record Last Update: 20260801T190356+0000

Ratings and Alerts

No rating or validation information has been found for QIAGEN.

No alerts have been found for QIAGEN.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 85828 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Clevenger AJ, et al. (2025) Oncogenic KRAS Mutations Confer a Unique Mechanotransduction Response to Peristalsis in Colorectal Cancer Cells. *Molecular cancer research : MCR*, 23(2), 128.

Tesi B, et al. (2025) Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(14), 3062.

Chatenoud H, et al. (2025) Metabolic comparison of minimally to noninvasive urogenital sample types for studying gynecologic health: A pilot study. *iScience*, 28(7), 112938.

Zhang L, et al. (2025) Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity That Associate with a Clinically Aggressive Subtype of Prostate Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(10), 2034.

Diamond B, et al. (2025) Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies. *Blood cancer discovery*, 6(5), 450.

Steiniche MM, et al. (2025) The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(22), 4720.

Klemm N, et al. (2025) The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect. *Cancer research*, 85(11), 1978.

Mathios D, et al. (2025) Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes. *Cancer discovery*, 15(8), 1593.

Wiggins JM, et al. (2025) Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(24), 5225.

VandenHeuvel SN, et al. (2025) Decellularized Extracellular Matrix Scaffolds to Engineer the Dormant Landscape of Microscopic Colorectal Cancer Liver Metastasis. *Advanced healthcare materials*, e01791.

Minko IG, et al. (2025) Aflatoxin B1-Induced Hepatic Mutagenesis in Mice Expressing Gene-Edited Neil1. *Environmental and molecular mutagenesis*, 66(4), 144.

Okechukwu CC, et al. (2025) CF10/LV overcomes acquired resistance to 5-FU/LV in colorectal cancer cells through downregulation of the c-Myc/ABCB5 axis. *Cancer drug resistance (Alhambra, Calif.)*, 8, 35.

Rebhun RB, et al. (2025) Phase 2 trial (NCI-COTC030) of adjuvant inhaled recombinant human IL-15 combined with amputation and adjuvant chemotherapy in dogs with appendicular osteosarcoma. *Frontiers in immunology*, 16, 1672790.

Markusson S, et al. (2025) Nanobodies against the myelin enzyme CNPase as tools for structural and functional studies. *Journal of neurochemistry*, 169(1), e16274.

Durán-Fuentes JA, et al. (2025) Repeatome diversity in sea anemone genomics (Cnidaria: Actiniaria) based on the Actiniaria-REPLib library. *BMC genomics*, 26(1), 473.

Kyriacou C, et al. (2025) Maternal plasma microRNAs as potential biomarkers for triaging pregnancies of unknown location and ectopic pregnancy diagnosis. *Non-coding RNA research*, 13, 162.

Pinto-Cardoso R, et al. (2025) HIF-1 α Stabilization Hampers the Chondrogenic Differentiation of Aged Bone Marrow Mesenchymal Stem Cells by Adenosine A2A/A2B Receptors Imbalance. *ACS pharmacology & translational science*, 8(7), 2075.

Cluzet V, et al. (2025) Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways. *Molecular cancer therapeutics*, 24(8), 1197.

Ray P, et al. (2025) SMURF2 Facilitates GAP17 Isoform 1 Membrane Displacement to Promote Mutant p53-KRAS Oncogenic Synergy. *Molecular cancer research : MCR*, 23(6), 530.

Chen XX, et al. (2025) Microbial dysbiosis with tryptophan metabolites alteration in lower respiratory tract is associated with clinical responses to anti-PD-1 immunotherapy in advanced non-small cell lung cancer. *Cancer immunology, immunotherapy : CII*, 74(4), 140.